Otsuka opts out of Cimzia in Japan as UCB alliance reshaped
This article was originally published in Scrip
Otsuka Pharmaceutical is to end its involvement in the Japanese development and commercialisation of UCB's pegylated antibody certolizumab pegol (Cimzia), although the firms will continue to work together on two other launched UCB products in the CNS field.
You may also be interested in...
Join us for a brief audio tour around the past week's key developments in the global biopharma industry, in this podcast version of Scrip's Five Must-Know Things.
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This biweekly selection of insights from our experienced on-the-ground team will help.
Plus deals involving Takeda/OrigiMed, Amcure/Hinova, AUM/Newsoara, Taiho/Lung Therapeutics, 3D Medicines/Aravive, HitGen/Baiyunshan, Dong-A/Jiangsu Hengrui, and Crescita/Juyou.